JCA Timelines & Regulatory Divergence

MarcusWelcome to Access Brief, the daily podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Tovorafenib JCA timelines, medical device JCAs, JSC submissions, Camizestrant divergence, and Mirvetuximab CDF. Let's get into it.

MarcusTovorafenib's second JCA report is out, and the procedural timeline implications are stark. The EU highlights capacity constraints causing delays in scientific advice and RWE integration. HTA bodies are struggling to keep pace with oncology assessments, creating bottlenecks that directly impact launch readiness. Companies must now build in buffer periods for JCA processes that weren't anticipated in original HTA timelines.

SaraAgreed, but the report's focus on PROs feels like a distraction. When timelines are compressed, forcing patient-reported outcomes into the assessment only dilutes the clinical evidence package. HTA bodies should prioritize hard endpoints over PROs when resources are constrained—it's a matter of efficiency.

MarcusThat's undervaluing PROs in oncology. They capture real-world benefits that survival metrics miss, especially in symptomatic diseases. Ignoring them risks misrepresenting value. The JCA isn't just about clinical efficacy; it's about holistic patient impact.

SaraMedical device JCAs went live in June, expanding to Class IIb and III devices. This harmonization across medicinal products and devices is long overdue, but the IVD methodology gaps are glaring. HTA bodies lack standardized approaches for diagnostics, creating inconsistent assessments that fragment evidence strategies.

MarcusThe expansion is necessary complexity. Medical devices require different evidence frameworks than drugs, and forcing one-size-fits-all HTA models would undermine innovation. The gaps are growing pains, not flaws.

SaraJSC submissions opened June 1st, emphasizing high-quality data. But the bar for 'high-quality' is subjective without clear metrics. Companies are investing heavily in RWE to meet these demands, yet HTA bodies still prioritize randomized trials. It's misaligned with real-world evidence adoption.

MarcusSubjectivity is inherent in HTA. RWE has its own biases—selection effects, confounding variables. Randomized trials remain the gold standard for causal inference. The JSC is right to demand rigor.

SaraCamizestrant's transatlantic divergence is creating HEOR chaos. Approved in the US but not EU, with different patient populations. Companies must now duplicate evidence generation for each region, doubling costs and fragmenting data strategies. It's an unsustainable burden for oncology drugs.

MarcusDuplication is inefficient, but the divergence allows for tailored evidence. The US approval generates real-world data that can inform EU submissions. Regional variation isn't a flaw—it's an opportunity for nuanced value demonstrations.

SaraMirvetuximab's interim CDF recommendation using preliminary RWE sets a concerning precedent. ADC portfolios are increasingly relying on accelerated evidence pathways, but interim RWE has long-term cost-effectiveness risks. HTA bodies are normalizing lower evidence thresholds for unmet needs.

MarcusThe CDF is designed for adaptive evidence. Interim RWE enables earlier access for life-threatening conditions, with reassessments built in. It's pragmatic, not risky—especially when survival benefits are clear.

SaraWe disagree on PROs, RWE standards, and evidence thresholds—but the common thread is HTA process strain. Capacity constraints, expansion pains, and divergence are reshaping evidence strategies. Companies must build flexibility into their HEOR roadmaps.

MarcusFlexibility is key, but so is evidence rigor. Navigating these tensions requires balancing pragmatism with scientific integrity. The market access landscape is evolving—adapt or get left behind.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.